Serum Institute of India

Serum Institute of India develops and manufactures a comprehensive portfolio of vaccines and immunobiologicals, positioning itself as the world's largest vaccine producer by volume. The company leverages advanced genetic and cell-based technologies to create critical immunizations, including those for polio, diphtheria, tetanus, measles, mumps, rubella, and COVID-19, among many others. Their technical approach emphasizes high-volume production while maintaining stringent quality and safety standards.

The company was founded in 1966 by Dr. Cyrus Poonawalla, driven by the insight to address the severe shortage and high cost of essential immunobiologicals in India. His vision was to establish domestic manufacturing capabilities, making vital treatments accessible and affordable. This initiative successfully led India to self-sufficiency in numerous life-saving vaccines, initially focusing on anti-toxins and subsequently expanding to a wide range of childhood immunizations.

Serum Institute’s products serve a global customer base, with an estimated 65% of children worldwide receiving at least one vaccine from the company. These vaccines are distributed across approximately 170 countries, often integrated into national immunization programs. The company’s long-term vision centers on a philanthropic commitment to continually reduce vaccine costs, ensuring that even the most underprivileged children globally receive protection from preventable diseases.